Michael Thomas

C. Gridelli, Michael Thomas, F. de Marinis, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Insulin-like growth factor 1 pathway mutations and protein expression in resected non-small cell lung cancer.

Michael Thomas, Arne Warth, Angela Risch, 2014, Human pathology.

Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non–small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study

Michael Thomas, N. Thatcher, J. Goldschmidt, 2019, Clinical Cancer Research.

Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma

S. Fröhling, M. Kriegsmann, P. Schirmacher, 2021, Cancer Immunology, Immunotherapy.

Mass Spectrometry Imaging for Reliable and Fast Classification of Non-Small Cell Lung Cancer Subtypes

R. Casadonte, M. Kriegsmann, J. Kriegsmann, 2020, Cancers.

Bevacizumab-based treatment as salvage therapy in patients with recurrent symptomatic brain metastases

D. Jäger, F. Marmé, Michael Thomas, 2020, Neuro-oncology advances.

Spatial and temporal heterogeneity of panel-based tumor mutational burden (TMB) in pulmonary adenocarcinoma: separating biology from technical artifacts.

S. Fröhling, M. Kriegsmann, A. Warth, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Cancer cell specific inhibition of Wnt/β-catenin signaling by forced intracellular acidification

C. Plass, A. Warth, C. Niehrs, 2018, Cell Discovery.

Progression of Pulmonary Function and Correlation with Survival Following Stereotactic Body Radiotherapy of Central and Ultracentral Lung Tumors

J. Debus, Michael Thomas, R. E. El Shafie, 2020, Cancers.

Safety and Efficacy of Stereotactic Body Radiotherapy in Ultracentral Lung Tumors Using a Risk-optimized Fractionation Scheme.

J. Debus, Michael Thomas, F. Weykamp, 2020, Clinical lung cancer.

The Multi-Modal Effect of the Anti-fibrotic Drug Pirfenidone on NSCLC

K. Rabe, W. Seeger, T. Goldmann, 2020, Frontiers in Oncology.

A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer

T. Zander, Michael Thomas, P. Iversen, 2019, Investigational New Drugs.

Validation of the T Descriptor (TNM-8) in T3N0 Non-Small-Cell Lung Cancer Patients; a Bicentric Cohort Analysis with Arguments for Redefinition

M. Kriegsmann, Michael Thomas, T. Muley, 2021, Zentralblatt für Chirurgie.

Adjuvant therapy for resectable high-risk soft tissue sarcoma: feasibility and efficacy of a sandwich chemoradiotherapy strategy

W. Winkelmann, N. Willich, Michael Thomas, 2012, Cancer Chemotherapy and Pharmacology.

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.

A. Mansfield, Michael Thomas, R. Doebele, 2021, The Lancet. Oncology.

Durvalumab in frail and elderly patients with stage four non-small cell lung cancer: Study protocol of the randomized phase II DURATION trial

A. Stenzinger, Michael Thomas, F. Lasitschka, 2020, Trials.

Quantifying potential confounders of panel-based tumor mutational burden (TMB) measurement.

S. Fröhling, W. Weichert, P. Schirmacher, 2020, Lung cancer.

A Phase II Trial of Nivolumab With Chemotherapy Followed by Maintenance Nivolumab in Patients With Pleural Mesothelioma After Surgery: The NICITA Study Protocol.

Michael Thomas, H. Bischoff, M. Feisst, 2020, Clinical lung cancer.

Correlation of EGFR mutations with chromosomal alterations and expression of EGFR, ErbB3 and VEGF in tumor samples of lung adenocarcinoma patients.

E. C. Xu, A. Jauch, H. Dienemann, 2008, Lung cancer.

Early Assessment of Chemotherapy Response in Advanced Non-Small Cell Lung Cancer with Circulating Tumor DNA

Ash A. Alizadeh, M. Kriegsmann, M. Diehn, 2022, Cancers.

Early palliative care for adults with advanced cancer.

G. Rücker, Michael Thomas, H. Friederich, 2017, The Cochrane database of systematic reviews.

Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial

Michael Thomas, J. Krisam, P. Christopoulos, 2020, BMC Cancer.

Surgical intervention for pulmonary metastases.

H. Dienemann, Michael Thomas, M. Bischof, 2012, Deutsches Arzteblatt international.

Conventional and semi-automatic histopathological analysis of tumor cell content for multigene sequencing of lung adenocarcinoma

M. Kriegsmann, J. Kriegsmann, R. Longuespée, 2021, Translational lung cancer research.

Impact and Safety of Adjuvant Chemotherapy on Pulmonary Function in Early Stage Non-Small Cell Lung Cancer

N. Reinmuth, I. Zuna, Michael Thomas, 2013, Respiration.

Pathways regulating the expression of the immunomodulatory protein glycodelin in non-small cell lung cancer

A. Warth, H. Sültmann, Michael Thomas, 2018, International journal of oncology.

Three‐Year Follow‐Up of a Randomized Phase II Trial on Refinement of Early‐Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study)

C. Schumann, Michael Thomas, M. Kreuter, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Prognostic significance of vessel architecture and vascular stability in non-small cell lung cancer.

N. Reinmuth, Michael Thomas, L. Freitag, 2007, Lung cancer.

Combined modality treatment for locally advanced non-small cell lung cancer: preoperative chemoradiation does not result in a poorer quality of life.

N. Willich, Michael Thomas, M. Semik, 2004, Lung cancer.

Preoperative chemotherapy with and without additional radiochemotherapy: benefit and risk for surgery of stage III non-small cell lung cancer.

H. Scheld, Michael Thomas, M. Semik, 2004, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA

A. Stenzinger, D. Kazdal, M. Schlesner, 2020, EBioMedicine.

Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non–small cell lung cancer

Michael Thomas, M. Brown, J. Schiller, 2013, Investigational New Drugs.

Polymorphisms in the Apoptotic Pathway Gene BCL-2 and Survival in Small Cell Lung Cancer

N. Reinmuth, H. Bartsch, Michael Thomas, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer

D. Atanackovic, Michael Thomas, S. Koch, 2019, Cancer Immunology, Immunotherapy.

Surgical Intervention for Pulmonary

H. Dienemann, Michael Thomas, M. Bischof, 2012 .

Totality of evidence in the development of ABP 215, an approved bevacizumab biosimilar.

Michael Thomas, Y. Ohe, N. Thatcher, 2019, Immunotherapy.

Durvalumab in frail and elder patients with stage four NSCLC: Study protocol of the randomized phase II DURATION trial

A. Stenzinger, Michael Thomas, F. Lasitschka, 2019 .

A mighty oak in the rapidly expanding field of checkpoint inhibition for NSCLC.

Michael Thomas, P. Christopoulos, 2017, Journal of thoracic disease.

Non-small-cell lung cancer: multimodality approach in stage-III resectable disease.

N. Reinmuth, Michael Thomas, M. Kreuter, 2004, Lung cancer.

Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy.

F. Cappuzzo, K. Syrigos, Michael Thomas, 2016, Lung cancer.

Germline Genetic Variants of the Renin-Angiotensin System, Hypoxia and Angiogenesis in Non-Small Cell Lung Cancer Progression: Discovery and Validation Studies

M. Kriegsmann, Michael Thomas, F. Herth, 2020, Cancers.

Synonymous EGFR variant p.Q787Q is neither prognostic nor predictive in patients with lung adenocarcinoma

A. Warth, P. Schirmacher, A. Stenzinger, 2017, Genes, chromosomes & cancer.

Randomized phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non–small cell lung cancer

Michael Thomas, Keunchil Park, T. Ciuleanu, 2016 .

Assessment of thymidylate synthase expression in biopsy specimens and corresponding resection specimens of non‐small‐cell lung cancer

A. Warth, H. Dienemann, P. Schirmacher, 2012, Histopathology.

Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non-Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial.

M. Socinski, N. Reinmuth, C. Gridelli, 2020, Clinical lung cancer.

Pharmacoenhancement of Low Crizotinib Plasma Concentrations in Patients with Anaplastic Lymphoma Kinase‐Positive Non‐Small Cell Lung Cancer using the CYP3A Inhibitor Cobicistat

W. Haefeli, Michael Thomas, G. Mikus, 2020, Clinical and translational science.

Lack of prognostic significance of neuroendocrine differentiation and stem cell antigen co-expression in resected early-stage non-small cell lung cancer.

Michael Thomas, F. Herth, P. Schnabel, 2013, Anticancer research.

COX‐2 upregulation in thymomas and thymic carcinomas

H. Dienemann, P. Schirmacher, Michael Thomas, 2006, International journal of cancer.

Intracranial and whole-body response of ceritinib in ALK inhibitor-naïve and previously ALK inhibitor-treated patients with ALK-rearranged non-small-cell lung cancer (NSCLC): updated results from the phase 1, multicentre, open-label ASCEND-1 trial

Michael Thomas, Armando Santoro, Martin Schuler, 2016, The Lancet. Oncology.

CD13 as target for tissue factor induced tumor vascular infarction in small cell lung cancer.

G. Lenz, E. Wardelmann, Michael Thomas, 2017, Lung cancer.

nab-Paclitaxel/Carboplatin in Vulnerable Populations With Advanced Non-Small Cell Lung Cancer: Pooled Analysis

M. Socinski, C. Gridelli, Michael Thomas, 2021, Frontiers in Oncology.

Paracrine interactions of vascular endothelial growth factor and platelet-derived growth factor in endothelial and lung cancer cells.

N. Reinmuth, Michael Thomas, W. Berdel, 2007, International journal of oncology.

Impact of inflammatory markers on survival in patients with limited disease small-cell lung cancer undergoing chemoradiotherapy

J. Debus, Michael Thomas, F. Herth, 2018, Cancer management and research.

Outcome and prognostic factors in patients with brain metastases from small-cell lung cancer treated with whole brain radiotherapy

A. Warth, J. Debus, Michael Thomas, 2017, Journal of Neuro-Oncology.

Nine‐year Experience: Prophylactic Cranial Irradiation in Extensive Disease Small‐cell Lung Cancer

J. Debus, Michael Thomas, F. Herth, 2017, Clinical lung cancer.

Assessing patient–caregiver communication in cancer—a psychometric validation of the Cancer Communication Assessment Tool (CCAT-PF) in a German sample

Michael Thomas, M. Hartmann, W. Herzog, 2014, Supportive Care in Cancer.

[Breast cancer in the early stage].

R. J. Jones, M. Espié, G. Giaccone, 2012, Gan no rinsho. Japan journal of cancer clinics.

Non-small cell lung cancer, locally advanced

P. Lambin, S. Kozlov, I. Petersen, 2012 .

Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC).

Michael Thomas, R. Doebele, G. Curigliano, 2019, Journal of Clinical Oncology.

Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.

H. Groen, T. Overbeck, Michael Thomas, 2020, The New England journal of medicine.

Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial

J. Debus, Michael Thomas, F. Lasitschka, 2019, BMC Cancer.

Combined anti‐PDGFRα and PDGFRβ targeting in non‐small cell lung cancer

N. Reinmuth, Michael Thomas, W. Berdel, 2009, International journal of cancer.

Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial.

Michael Thomas, A. Shaw, Gregory Riely, 2014 .

Histological and molecular plasticity of ALK-positive non-small-cell lung cancer under targeted therapy: a case report

M. Kriegsmann, D. Kazdal, Michael Thomas, 2022, Cold Spring Harbor molecular case studies.

Efficacy and Safety of Ceritinib in Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Rearranged (ALK+) Non-Small Cell Lung Cancer (NSCLC): An Update of ASCEND-1

Michael Thomas, A. Shaw, Gregory Riely, 2014 .

BM-32CERITINIB (LDK378) FOR TREATMENT OF PATIENTS WITH ALK-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES (BM) IN THE ASCEND-1 TRIAL

Michael Thomas, A. Shaw, Gregory Riely, 2014 .

Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases

Olaf Neumann, Michael Thomas, Ivo Buchhalter, 2019, International journal of cancer.

Early Development of Ubiquitous Acanthocytosis and Extravascular Hemolysis in Lung Cancer Patients Receiving Alectinib

Michael Thomas, M. Hundemer, K. Kriegsmann, 2022, Cancers.

Trimodal therapy for stage III-N2 non-small-cell lung carcinoma: a single center retrospective analysis

J. Debus, Michael Thomas, M. Bischof, 2014, BMC Cancer.

HER2/neu expression and amplification in non-small cell lung cancer prior to and after neoadjuvant therapy.

K. Müller, Michael Thomas, A. Heinecke, 2005, Lung cancer.

Genetic landscape of ALK+ non-small cell lung cancer (NSCLC) patients (pts) and response to ceritinib in ASCEND-1.

Serafino Pantano, Michael Thomas, A. Shaw, 2016 .

Role of Synaptophysin, Chromogranin and CD56 in adenocarcinoma and squamous cell carcinoma of the lung lacking morphological features of neuroendocrine differentiation: a retrospective large-scale study on 1170 tissue samples

M. Kriegsmann, A. Warth, A. Stenzinger, 2021, BMC Cancer.

Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).

Michael Thomas, G. Rustin, N. Lemoine, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Brief Report: Efficacy of immune checkpoint inhibitors alone or in combination with chemotherapy in NSCLC harboring ERBB2 mutations.

D. Aust, A. Stenzinger, Michael Thomas, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential Biomarker.

G. Scagliotti, R. Plummer, Michael Thomas, 2015, Clinical lung cancer.

Identification of metastasis-associated receptor tyrosine kinases in non-small cell lung cancer.

Michael Thomas, S. Diederichs, W. Berdel, 2005, Cancer research.

EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype

A. Warth, H. Dienemann, W. Weichert, 2013, European Respiratory Journal.

DNA methylation profiles of bronchoscopic biopsies for the diagnosis of lung cancer

R. Siebert, K. Rabe, T. Goldmann, 2021, Clinical epigenetics.

Stage-specific embryonic antigen-4 is expressed in basaloid lung cancer and associated with poor prognosis

A. Warth, Michael Thomas, F. Herth, 2012, European Respiratory Journal.

A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma

S. Fröhling, M. Kriegsmann, P. Schirmacher, 2021, Oncoimmunology.

Glycodelin: A New Biomarker with Immunomodulatory Functions in Non–Small Cell Lung Cancer

A. Warth, H. Dienemann, Michael Thomas, 2015, Clinical Cancer Research.

Variant classification in precision oncology

Melanie Boerries, Olaf Neumann, Michael Thomas, 2019, International journal of cancer.

Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real‐life analysis of three larger gene panels

Olaf Neumann, Michael Thomas, Ivo Buchhalter, 2019, International journal of cancer.

Size matters: Dissecting key parameters for panel‐based tumor mutational burden analysis

Olaf Neumann, Michael Thomas, Ivo Buchhalter, 2018, International journal of cancer.

Implementing tumor mutational burden (TMB) analysis in routine diagnostics-a primer for molecular pathologists and clinicians.

Olaf Neumann, Michael Thomas, Jan Budczies, 2018, Translational lung cancer research.

Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer

N. Reinmuth, A. Reuss, R. Penzel, 2015, European Respiratory Journal.

Expression and mutation analysis of EGFR, c-KIT, and β-catenin in pulmonary blastoma

H. Dienemann, P. Schirmacher, R. Penzel, 2011, Journal of Clinical Pathology.

Targeting rare and non-canonical driver variants in NSCLC - An uncharted clinical field.

S. Fröhling, M. Kriegsmann, P. Schirmacher, 2021, Lung cancer.

Genome-wide DNA methylation profiling in early stage I lung adenocarcinoma reveals predictive aberrant methylation in the promoter region of the long non-coding RNA PLUT - an exploratory study.

C. Plass, M. Esteller, A. Warth, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Next-generation sequencing facilitates detection of the classic E13-A20 EML4-ALK fusion in an ALK-FISH/IHC inconclusive biopsy of a stage IV lung cancer patient: a case report

A. Warth, P. Schirmacher, A. Stenzinger, 2016, Diagnostic Pathology.

Low Input Whole-Exome Sequencing to Determine the Representation of the Tumor Exome in Circulating DNA of Non-Small Cell Lung Cancer Patients

E. Dahl, H. Sültmann, Michael Thomas, 2016, PloS one.

Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival

P. Schirmacher, A. Stenzinger, J. Budczies, 2019, Cancers.

Combination of Mesothelin and CEA Significantly Improves the Differentiation between Malignant Pleural Mesothelioma, Benign Asbestos Disease, and Lung Cancer

H. Dienemann, Michael Thomas, F. Herth, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A blood-based miRNA signature with prognostic value for overall survival in advanced stage non-small cell lung cancer treated with immunotherapy

K. Rabe, R. Horos, Michael Thomas, 2022, npj Precision Oncology.

Deep Learning for the Classification of Small-Cell and Non-Small-Cell Lung Cancer

Michael Thomas, Cleo-Aron Weis, Claus Peter Heussel, 2020, Cancers.

Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study

P. Schirmacher, M. Dietel, Michael Thomas, 2018, BMC Cancer.

EGFR Mutation Status and First-Line Treatment in Patients with Stage III/IV Non–Small Cell Lung Cancer in Germany: An Observational Study

C. Schumann, P. Schirmacher, M. Dietel, 2015, Cancer Epidemiology, Biomarkers & Prevention.

Optimized algorithm for Sanger sequencing-based EGFR mutation analyses in NSCLC biopsies

A. Warth, P. Schirmacher, M. Dietel, 2012, Virchows Archiv.

Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop

Michael Thomas, Federico Cappuzzo, Manfred Dietel, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.

G. Scagliotti, N. Hanna, Michael Thomas, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mutational status of the epidermal growth factor receptor (EGFR) gene in thymomas and thymic carcinomas.

E. C. Xu, H. Dienemann, P. Schirmacher, 2007, Cancer letters.

Feasibility and Challenges for Sequential Treatments in ALK-Rearranged Non-Small-Cell Lung Cancer

M. Kriegsmann, A. Stenzinger, D. Kazdal, 2021, Frontiers in Oncology.

Glycodelin as a Serum and Tissue Biomarker for Metastatic and Advanced NSCLC

A. Warth, Michael Thomas, F. Herth, 2018, Cancers.

The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival.

Michael Thomas, Jan Budczies, Wilko Weichert, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315).

W. Weichert, A. Stenzinger, Michael Thomas, 2020, Lung cancer.

Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer

M. Kriegsmann, P. Schirmacher, A. Stenzinger, 2021, Therapeutic advances in medical oncology.

Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer

Michael Thomas, Keunchil Park, T. Ciuleanu, 2017, British Journal of Cancer.

Non-small cell lung cancer is characterized by dramatic changes in phospholipid profiles

H. Dienemann, R. Caprioli, S. Bordel, 2015, International journal of cancer.

Phospholipid profiling identifies acyl chain elongation as a ubiquitous trait and potential target for the treatment of lung squamous cell carcinoma

H. Dienemann, R. Caprioli, Michael Thomas, 2016, Oncotarget.

Activation of AMP-activated protein kinase sensitizes lung cancer cells and H1299 xenografts to erlotinib.

H. Fröhlich, H. Sültmann, R. Herwig, 2014, Lung cancer.

Signal transduction pathways as novel therapy targets in lung cancer.

N. Reinmuth, Michael Thomas, W. Berdel, 2004, Lung cancer.

Characteristics of lung cancer after a previous malignancy.

N. Reinmuth, Michael Thomas, F. Herth, 2014, Respiratory medicine.

Characteristics and outcome of patients with second primary lung cancer

A. Warth, N. Reinmuth, Michael Thomas, 2012, European Respiratory Journal.

AURKA, DLGAP5, TPX2, KIF11 and CKAP5: Five specific mitosis-associated genes correlate with poor prognosis for non-small cell lung cancer patients

Michael Thomas, Arne Warth, Petros Christopoulos, 2017, International journal of oncology.

Interferon Regulatory Factor 9 Promotes Lung Cancer Progression via Regulation of Versican

M. Kriegsmann, W. Seeger, Michael Thomas, 2021, Cancers.

Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.

Michael Thomas, Yi-long Wu, E. Felip, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Andreas Sashegyi, Michael Thomas, Federico Cappuzzo, 2014, The Lancet.

Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 Inhibitors

H. Kauczor, M. Kriegsmann, A. Stenzinger, 2020, Cancers.

S100 Family Members and Trypsinogens Are Predictors of Distant Metastasis and Survival in Early-Stage Non-Small Cell Lung Cancer

Michael Thomas, P. Ji, L. Tickenbrock, 2004, Cancer Research.

Whole brain radiation therapy alone versus radiosurgery for patients with 1–10 brain metastases from small cell lung cancer (ENCEPHALON Trial): study protocol for a randomized controlled trial

J. Debus, Michael Thomas, C. Heussel, 2018, Trials.

Taking ACTION to establish direct costs and outcomes of treating advanced non-small cell lung cancer in routine clinical practice.

Michael Thomas, A. Szczepura, M. Cullen, 2004, Lung cancer.

EGFR-TKI resistant non-small cell lung cancer (NSCLC): new developments and implications for future treatment.

Michael Thomas, W. Brugger, 2012, Lung cancer.

Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3‐Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations

A. Bardia, Michael Thomas, P. LoRusso, 2019, The oncologist.

Molecular determinants of response to RTK‐targeting agents in nonsmall cell lung cancer

H. Dienemann, N. Reinmuth, Michael Thomas, 2006, International journal of cancer.

MINI REVIEW Molecular determinants of response to RTK-targeting agents in nonsmall cell lung cancer

H. Dienemann, N. Reinmuth, Michael Thomas, 2006 .

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.

C. Gridelli, Michael Thomas, F. de Marinis, 2012, The Lancet. Oncology.

Glycodelin is a potential novel follow-up biomarker for malignant pleural mesothelioma

A. Warth, H. Dienemann, Michael Thomas, 2016, Oncotarget.

Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis

A. Stenzinger, M. Schlesner, H. Sültmann, 2021, npj Precision Oncology.

Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: First clinical experience.

M. Kriegsmann, U. Haberkorn, Michael Thomas, 2021, Lung cancer.

Paclitaxel for treatment of advanced small cell lung cancer (SCLC): a retrospective study of 185 patients

Michael Thomas, T. Muley, M. Steins, 2020, Journal of thoracic disease.

Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinib.

Michael Thomas, M. Schuler, C. Grohé, 2014, The oncologist.

Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer

Michael Thomas, R. Huber, M. Reck, 2013, European Respiratory Journal.

First-line systemic treatment with gefitinib in stage IV non-small cell lung cancer.

Michael Thomas, W. Berdel, H. Serve, 2005, Oncology reports.

The gefitinib long-term responder (LTR)--a cancer stem-like cell story? Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP).

R. Penzel, Michael Thomas, P. Schnabel, 2012, Lung cancer.

PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.

C. Gridelli, Michael Thomas, F. de Marinis, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Deficient CD247 expression is a typical histopathological characteristic of thymomas with cortical features

A. Marx, Michael Thomas, T. Muley, 2018, Histopathology.

Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial.

G. Scagliotti, R. Govindan, J. Strausz, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab

N. Reinmuth, A. Reuss, Michael Thomas, 2019, Oncology letters.

ERCC1 assessment in upfront treatment with and without cisplatin-based chemotherapy in stage IIIB/IV non-squamous non-small cell lung cancer

N. Reinmuth, A. Reuss, Michael Thomas, 2018, Medical Oncology.

Fibroblast Growth Factor—14 Acts as Tumor Suppressor in Lung Adenocarcinomas

M. Kriegsmann, W. Seeger, Michael Thomas, 2020, Cells.

Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer.

Michael Thomas, Wolfgang E Berdel, N. Reinmuth, 2002, Lung cancer.

A comprehensive study of polymorphisms in ABCB1, ABCC2 and ABCG2 and lung cancer chemotherapy response and prognosis

Michael Thomas, A. Risch, D. Campa, 2012, International journal of cancer.

Identification of metastasis-associated receptor tyrosine kinases in non-small cell lung cancer.

Michael Thomas, S. Diederichs, W. Berdel, 2005, Cancer research.

Genome-wide screening for prognosis-predicting genes in early-stage non-small-cell lung cancer.

Michael Thomas, Carsten Müller-Tidow, Hubert Serve, 2004, Lung cancer.

Advances in Brief S 100 Family Members and Trypsinogens Are Predictors of Distant Metastasis and Survival in Early-Stage Non-Small Cell Lung Cancer

Michael Thomas, P. Ji, L. Tickenbrock, 2004 .

Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer

M. Kriegsmann, A. Stenzinger, D. Kazdal, 2021, Frontiers in Oncology.

POSITIVE study: physical exercise program in non-operable lung cancer patients undergoing palliative treatment

C. Ulrich, Michael Thomas, U. Abel, 2016, BMC Cancer.

Trimodality treatment in Stage III nonsmall cell lung carcinoma

Michael Thomas, L. Freitag, W. Berdel, 2002, Cancer.

Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC).

Michael Thomas, R. Doebele, G. Curigliano, 2020 .

KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315).

W. Weichert, A. Stenzinger, Michael Thomas, 2021, Lung cancer.

Earlier extracranial progression and shorter survival in ALK-rearranged lung cancer with positive liquid rebiopsies

M. Kriegsmann, A. Stenzinger, D. Kazdal, 2021, Translational lung cancer research.

Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in KLC1–ALK-rearranged lung cancer

A. Stenzinger, M. Schlesner, Michael Thomas, 2019, Cold Spring Harbor molecular case studies.

Defining molecular risk in ALK+ NSCLC

A. Stenzinger, J. Budczies, H. Sültmann, 2019, Oncotarget.

EML4‐ALK fusion variant V3 is a high‐risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ non‐small cell lung cancer

A. Warth, P. Schirmacher, A. Stenzinger, 2018, International journal of cancer.

Trial on Refinement of Early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: The TREAT protocol

H. Dienemann, Michael Thomas, M. Kreuter, 2007, BMC Cancer.

Outcome and prognostic factors in single brain metastases from small-cell lung cancer

A. Warth, A. Unterberg, J. Debus, 2018, Strahlentherapie und Onkologie.

Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer.

F. Cappuzzo, Michael Thomas, F. Shepherd, 2017, Lung cancer.

The cancer stem cell antigens CD133, BCRP1/ABCG2 and CD117/c-KIT are not associated with prognosis in resected early-stage non-small cell lung cancer.

A. Warth, H. Dienemann, Michael Thomas, 2011, Anticancer research.

Consolidation Immunotherapy After Platinum-Based Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer—Cross-Sectional Study of Eligibility and Administration Rates

J. Debus, Michael Thomas, C. Heussel, 2020, Frontiers in Oncology.

Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial

Michael Thomas, F. Lasitschka, H. Bischoff, 2019, BMC Cancer.

Outcome in patients with small cell lung cancer re-irradiated for brain metastases after prior prophylactic cranial irradiation.

J. Debus, Michael Thomas, L. König, 2016, Lung cancer.

Large cell neuroendocrine lung carcinoma induces peripheral T-cell repertoire alterations with predictive and prognostic significance.

Michael Thomas, P. Schnabel, T. Muley, 2018, Lung cancer.

Early palliative care for improving quality of life and survival time in adults with advanced cancer: Meta-analytical findings from a Cochrane Review.

Michael Thomas, H. Friederich, M. Hartmann, 2016 .

Phase I and Pharmacokinetic Study of Pemetrexed plus Cisplatin in Chemonaive Patients with Locally Advanced or Metastatic Malignant Pleural Mesothelioma or Non–Small Cell Lung Cancer

Michael Thomas, J. Latz, L. Musib, 2009, Clinical Cancer Research.

Outcome and prognostic factors of multimodal therapy for pulmonary large-cell neuroendocrine carcinomas

A. Warth, J. Debus, Michael Thomas, 2015, European Journal of Medical Research.

Phase III Study of Crizotinib Versus Pemetrexed or Docetaxel Chemotherapy in Patients with Advanced Alk-Positive Non-Small Cell Lung Cancer (NSCLC) (Profile 1007)

P. Jänne, K. O'Byrne, Michael Thomas, 2012 .

A randomized, phase 3 study of datopotamab deruxtecan (Dato-DXd; DS-1062) versus docetaxel in previously treated advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (TROPION-Lung01).

Michael Thomas, Melissa L. Johnson, K. Yoh, 2021 .

OA07.08 HUDSON: An Open-Label, Multi-Drug, Biomarker-Directed, Phase II Platform Study in Patients with NSCLC, who Progressed on Anti-PD(L)1 Therapy

S. Barry, Michael Thomas, N. Rizvi, 2021 .

Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR- Expressing Squamous Non-Small-Cell Lung Cancer: German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE)

C. Kropf-Sanchen, M. Socinski, Michael Thomas, 2016, Oncology Research and Treatment.

MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small cell lung cancer.

Michael Thomas, E. Felip, S. Shreeve, 2021, Future Oncology.

Combined treatment of nonsmall cell lung cancer NSCLC stage III with intensity‐modulated RT radiotherapy and cetuximab

K. Herfarth, U. Haberkorn, J. Debus, 2011, Cancer.

Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer.

Michael Thomas, S. Thongprasert, P. Sunpaweravong, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcome and prognostic factors of postoperative radiation therapy (PORT) after incomplete resection of non-small cell lung cancer (NSCLC).

A. Warth, H. Dienemann, J. Debus, 2016, Lung cancer.

Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report

M. Kriegsmann, A. Stenzinger, D. Kazdal, 2021, Case Reports in Oncology.

Generation of a New Disease‐specific Prognostic Score for Patients With Brain Metastases From Small‐cell Lung Cancer Treated With Whole Brain Radiotherapy (BMS‐Score) and Validation of Two Other Indices

A. Warth, J. Debus, Michael Thomas, 2017, Clinical lung cancer.

Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy

M. Socinski, G. Scagliotti, Michael Thomas, 2020, ESMO Open.

Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patients

H. Sültmann, Michael Thomas, T. Muley, 2016, Scientific Reports.

Pemetrexed with or without Matuzumab as Second-Line Treatment for Patients with Stage IIIB/IV Non-small Cell Lung Cancer

M. Socinski, R. Kurek, Michael Thomas, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clonality of multifocal nonsmall cell lung cancer: implications for staging and therapy

A. Warth, P. Schirmacher, R. Penzel, 2011, European Respiratory Journal.

Early palliative care for improving quality of life and survival time in adults with advanced cancer

G. Rücker, Michael Thomas, H. Friederich, 2014 .

Ceritinib in Asian versus Caucasian patients (Pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) NSCLC: Subgroup analysis of the ASCEND-1 trial.

Michael Thomas, A. Shaw, Gregory Riely, 2014 .

Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial

A. Stenzinger, Michael Thomas, J. Krisam, 2021, BMC cancer.

Correction: Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non–small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study

Michael Thomas, N. Thatcher, J. Goldschmidt, 2019, Clinical Cancer Research.

Combined use of (18)F-FDG and (18)F-FMISO in unresectable non-small cell lung cancer patients planned for radiotherapy: a dynamic PET/CT study.

Michael Thomas, Christian Thieke, Uwe Haberkorn, 2015, American journal of nuclear medicine and molecular imaging.

Treatment and outcome of patients with metastatic NSCLC: a retrospective institution analysis of 493 patients

N. Reinmuth, Michael Thomas, F. Herth, 2013, Respiratory Research.

Targeting the Epidermal Growth Factor Receptor in Non-Small Cell Lung Cancer

N. Reinmuth, Michael Thomas, H. Bischoff, 2010, Oncology Research and Treatment.

A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer.

C. Schumann, Michael Thomas, J. Bosch-Barrera, 2017, Lung cancer.

De Novo Versus Secondary Metastatic EGFR-Mutated Non-Small-Cell Lung Cancer

M. Kriegsmann, A. Stenzinger, D. Kazdal, 2021, Frontiers in Oncology.

nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy

Edward S. Kim, M. Socinski, C. Gridelli, 2017, Lung Cancer.

Cancer cell specific inhibition of Wnt/β-catenin signaling by forced intracellular acidification

C. Plass, A. Warth, C. Niehrs, 2018, Cell Discovery.

Intracranial and whole-body response of ceritinib in ALK inhibitor-naïve and previously ALK inhibitor-treated patients with ALK-rearranged non-small-cell lung cancer ( NSCLC ) : updated results from the phase 1 , multicentre , open-label ASCEND-1 trial

Michael Thomas, A. Shaw, Gregory Riely, 2016 .

Comprehensive serial biobanking in advanced NSCLC: feasibility, challenges and perspectives

A. Warth, A. Stenzinger, U. Klingmüller, 2020, Translational lung cancer research.

Reflection of illness and strategies for handling advanced lung cancer – a qualitative analysis in patients and their relatives

Michael Thomas, D. Ose, J. Szecsenyi, 2017, BMC Health Services Research.

The pregnancy associated protein glycodelin as a follow-up biomarker in a male non-small cell lung cancer patient

H. Dienemann, Michael Thomas, F. Herth, 2015 .

A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer

N. Reinmuth, Michael Thomas, M. Schuler, 2021, Therapeutic advances in medical oncology.

KRAS-mutation positive, metastatic tonsil carcinoma with cancer stem-like cell features and long-term response to gefitinib: a case report and review of the literature.

R. Penzel, Michael Thomas, P. Schnabel, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.

C. Gridelli, Michael Thomas, F. de Marinis, 2014, Clinical lung cancer.

Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial).

J. S. Lee, D. R. Berry, G. Giaccone, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Endogenous anti-β-glucan antibodies as a potential predictive biomarker for clinical response to imprime PGG immunotherapy in non-small cell lung cancer (NSCLC) patients.

Michael Thomas, F. Schneller, D. McMurray, 2014 .

Open, randomized, multi-center phase II study comparing efficacy and tolerability of Erlotinib vs. Carboplatin/Vinorelbin in elderly patients (>70 years of age) with untreated non-small cell lung cancer.

Michael Thomas, P. Schnabel, C. Kortsik, 2014, Lung cancer.

Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: A randomized, double-blind phase III trial (ZEST).

Michael Thomas, S. Thongprasert, P. Sunpaweravong, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Six single-nucleotide polymorphisms in apoptotic genes and chemotherapy outcome in lung cancer patients

H. Bartsch, Michael Thomas, C. Heussel, 2008 .

Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial

Michael Thomas, F. Lasitschka, H. Bischoff, 2019, BMC Cancer.

Comparison of two ERCC1 antibodies as prognostic and predictive biomarkers for early non-small cell lung cancer.

A. Warth, H. Dienemann, Michael Thomas, 2014, Anticancer research.

Ion therapy within the trimodal management of superior sulcus tumors: the INKA trial

K. Herfarth, H. Dienemann, J. Debus, 2015, BMC Cancer.

MA11.05 Tepotinib in Patients with MET exon 14 (METex14) Skipping Advanced NSCLC: Updated Efficacy Results from VISION Cohort A

Yi-Wei Chen, Michael Thomas, E. Smit, 2021 .

Michael Thomas, E. Smit, P. Paik, 2020 .

Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study